Susquehanna Private Capital, a middle market private equity firm, has invested in Spherix Global insights, a pharmaceutical market insights firm concentrated on dermatology, gastroenterology, nephrology, neurology, ophthalmology, and rheumatology specialties.
Spherix offers pharmaceutical market insights and intelligence through its proprietary network of 3,000 active specialty providers and patients. The firm’s broad client base provides them with products that track the full therapeutic lifestyle. Spherix provides a comprehensive suite of offerings across specialties and indications.
“This is an exceptional day for Spherix and we are thrilled to embark on our next phase of growth in partnership with SPC,” added Jennifer and Kevin Robinson, Spherix founders. “By leveraging SPC’s guidance and financial resources, we will seek to continue scaling Spherix by expanding the reach of our network – with deeper insights into more specialty pharma markets, as well as geographies.”
360 Ventures, LLC acted as exclusive financial advisor and WilmerHale and Walder Wyss served as legal advisors to Spherix. Troutman Pepper served as legal advisor to SPC. Monroe Capital provided debt financing to support the transaction.